Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
FTH EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Faeth Therapeutics, Inc.NASDAQ: FTH
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$2.84, compared with -$3.91 a year earlier. Trailing-twelve-month EPS (Basic) was -$141.65.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly EPS (Basic) holds near -$2.84 or moves back toward the trailing-twelve-month quarterly average of -$35.41.
Sources:Income StatementText generated from reported figures; not investment advice.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (16.72) USD
- Year-over-year change
- +30.4%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (16.72) | +30.4% |
| FY2024 | 2024-12-31 | (24.01) | +1.6% |
| FY2023 | 2023-12-31 | (24.40) | +22.9% |
| FY2022 | 2022-12-31 | (31.65) | -19.2% |
| FY2021 | 2021-12-31 | (26.56) | — |
EPS (Basic) vs competitors
How FTH compares with its peers on the latest reported figures
- FTH's LTM Jun 2026 EPS (Basic) of -$141.65 is the lowest of the 10 companies compared; the peer median is -$1.57.
- Its year-over-year change of -564.7% is the lowest of 10, against a peer median of +18.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.5 | -35.2% | +212.1% | |
| LTM Jun 2026 | -$0.43 | +31.0% | — | |
| LTM Mar 2026 | -$1.06 | +37.3% | — | |
| LTM Sep 2026 | -$1.38 | -51.6% | — | |
| LTM Jun 2026 | -$1.57 | +19.5% | — | |
| LTM Mar 2026 | -$1.84 | -35.3% | — | |
| LTM Mar 2026 | -$2.5 | +18.3% | — | |
| LTM Mar 2026 | -$2.5 | +30.0% | — | |
| LTM Mar 2026 | -$3.35 | -59.5% | — | |
| LTM Jun 2026 | -$141.65 | -564.7% | — | |
| Peer median (excluding FTH) | -$1.57 | +18.3% | +212.1% | |
Competitors are the stored peer set for FTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 685K | 1.81M | 571K | 551K | 0 |
| Gross Profit | (685K) | (1.81M) | (571K) | (551K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.66M | 29.58M | 18.3M | 18.63M | 10.96M |
| Selling, General & Admin | 15.14M | 17.73M | 18.77M | 12.49M | 11.33M |
| Operating Expenses | 36.8M | 47.31M | 36.49M | 31.11M | 22.29M |
| Depreciation & Amortization | 685K | 1.81M | 3.68M | 551K | 139K |
| EBITDA | (35.44M) | (46.56M) | (33.39M) | (29.52M) | (20.91M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.48M) | (49.12M) | (37.06M) | (31.66M) | (22.29M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 800K | 1.78M | 3.62M | 2.55M | 1.24M |
| Interest Expense | 670K | 219K | 144K | 90K | 32K |
| Other Income / Expenses | 688K | 532K | 2.96M | 1.51M | 1.2M |
| Income Before Tax | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| EPS (Diluted) | (26.56) | (31.65) | (24.40) | (24.01) | (16.72) |
| Weighted Avg Shares | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
| Weighted Avg Shares (Diluted) | 1.39M | 1.54M | 1.4M | 1.26M | 1.26M |
Faeth Therapeutics, Inc.
NASDAQ:FTH
Intrinsic Alpha fair value
Locked
Current Price
$8.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.